Navigation Links
Yongye Biotechnology International Announces Second Quarter Results
Date:8/18/2008

27,442,191 12,863,821

PROPERTY AND EQUIPMENT, NET 551,545 2,486,487

INTANGIBLE ASSETS, NET 117,610 3,665,584

LONG-TERM INVESTMENTS -- 4,115,764

TOTAL ASSETS $28,111,346 $23,131,656

CURRENT LIABILITIES

Accounts Payable and

Accrued Expenses 1,882,643 1,271,852

Accounts Payable 4,889,694 --

Short-term Bank Loan -- 5,484,000

Due to Shareholders -- 2,507,371

Due to Related Parties 2,411,105 --

Tax Payables 406,530 893,892

Other Payables 40,424 50,916

Total Current Liabilities 9,630,396 10,208,031

LONG-TERM SHAREHOLDER LOANS -- 12,153

Minority Interest 1,135,005 --

STOCKHOLDERS' EQUITY

Capital Stock: 20,000,374

shares authorized and issued

par value $.001 as of June 30, 2008 20,000 --

Capital Contribution -- 7,260,000

Additional Paid-in Capital 9,200,092 --

Retained Earnings 6,939,975 4,024,111

Statutary Reserve 771,107 480,629

Accumulated other

Comprehensive Income 414,771 1,146,732

Total Stockholders' Equity $17,345,945 $12,911,472

TOTAL LIABILITIES AND

STOCKHOLDERS' EQUITY $28,111,346 $23,131,656
'/>"/>

SOURCE Yongye Biotechnology International, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Yongye Biotechnology International Announces Conference Call to Discuss Second Quarter 2008 Results
2. Yongye Biotechnology International Retains CCG Investor Relations
3. Yongye Biotechnology International, Inc. Appoints New Independent Auditor
4. Yongye Biotechnology Completes Reverse Merger and Completes $10.0 Million Private Financing
5. InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625
6. New Book on the Business of Biotechnology
7. InNexus Biotechnology CEO and Chief Scientific Officer to Present at IBCs Annual World Congress Conference in Boston on Aug 6th
8. Champions Biotechnology Reports Fiscal 2008 Full-Year Financial Results
9. Athera Biotechnology Founder Johan Frostegard and His Colleagues Win NACB Distinguished Abstract Award at AACC 2008
10. Pennsylvania Governor Rendell Says State Number 1 in New Biotechnology Study
11. WuXi PharmaTech (NYSE: WX) Wins the 2008 Frost & Sullivan Award for Best in Class Outsourced R&D in Pharmaceuticals and Biotechnology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... , Aug. 31, 2015 Research and Markets ... "Argentina Biomedical Sensors Market - Growth, Trends & ... The Argentina Biomedical Sensors market is estimated at ... over the period 2014-2020 The near future ... genetic formulation of each individual. These sensors can be ...
(Date:8/31/2015)... -- For people with Down syndrome, news from Elixirgen, ... located in the Science + Technology Park at Johns ... yet for people with Down syndrome and other chromosome disorders ... and Edwards syndrome aneuploidies in human cell cultures, " ... plans to develop this technology into a treatment for ...
(Date:8/31/2015)... SHANGHAI , Aug. 31, 2015 /PRNewswire/ ... next-generation antibiotics, today announced positive top-line results from ... lead drug candidate MRX-I. MRX-I is an oral ... as MRSA and VRE, while offering physicians and ... than currently available oxazolidinone agents. ...
(Date:8/31/2015)... ... August 31, 2015 , ... Regulatory agencies have ... drug development approval process. Thus, innovator companies must understand what will be needed ... Chicago-based CMO, has been hosting multiple educational panels and seminars for experts to ...
Breaking Biology Technology:Argentina Biomedical Sensors Market Report 2015 - Growth, Trends & Forecasts 2014-2020 2New Down syndrome therapy discovered 2MicuRX Reports Positive Top-Line Results In Phase 2 Clinical Trial For Novel Antibiotic MRX-I In Complicated Skin And Soft Tissue Infections 2Regis Shares Expert Advice on Impurities in Drug Development 2Regis Shares Expert Advice on Impurities in Drug Development 3
... ground-breaking treatment option for victims of whiplash associated disorders (WAD). ... Z Therapy is the first and only rehabilitation specialist in North ... neck pain. , ... Dallas, TX (PRWEB) April 21, ...
... NxStage Medical, Inc. (Nasdaq: NXTM ), a ... to release its financial results for the first quarter ... before the opening of the financial markets.NxStage will also ... on Friday, May 8, 2009 to discuss its first ...
... LLC announced today that it has issued an Executive ... 56-page report can be found at www.crystalra.com ... is a closely held pharmaceutical company focused exclusively on ... a technology spinout from Bayer HealthCare LLC, ACT Biotech ...
Cached Biology Technology:Z Therapy Is The First In North Texas To Offer Revolutionary Treatment Option For Neck Pain Sufferers 2NxStage to Report First Quarter 2009 Financial Results 2Crystal Research Associates, LLC Issues an Executive Informational Overview(R) (EIO(R)) on ACT Biotech, Inc. 2Crystal Research Associates, LLC Issues an Executive Informational Overview(R) (EIO(R)) on ACT Biotech, Inc. 3
(Date:7/31/2015)... julio de 2015 BGI llevará a cabo la ... 22 al 25 de octubre de 2015, en ... celebra su décimo aniversario este año. Desde su inauguración ... las reuniones anuales más influyentes del mundo en los ... conferencias científicas más dinámicas, entusiastas y amenas. ...
(Date:7/31/2015)... Chine, 31 juillet 2015 La 10e ... ) sera organisée par le BGI du 22 ... en Chine. La conférence ... inauguration en 2006, l,ICG est devenue l,une des ... domaine des « omiques » et c,est aussi la plus ...
(Date:7/31/2015)... 31. Juli 2015 Die 10. internationale Konferenz zu ... veranstaltet und findet vom 22. bis 25. Oktober ... statt. Die Konferenz feiert in ... 2006 ist die ICG weltweit zu einem der ... ist eines der dynamischsten, enthusiastischsten und angenehmsten wissenschaftlichen ...
Breaking Biology News(10 mins):La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 2La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 3Die 10. internationale Konferenz zu Genomik (ICG-10) beginnt im Oktober 2Die 10. internationale Konferenz zu Genomik (ICG-10) beginnt im Oktober 3
... faced with everyday obstacles in their physical environments and ... with them. Navigating these obstacles can involve highly complex ... work, researchers have employed an ingenious obstacle-based system for ... in the fruit fly Drosophila. , The findings ...
... tailored therapiesContinuing its strong support for studies on ... Institutes of Health anticipates spending more than $150 ... Research Network (PGRN). The research of this nationwide ... drug prescriptions to people's unique genetic make-ups. ...
... have found a family of proteins that enhances the sensitivity ... growth and cancer. Their discovery could lead to a completely ... new drugs to stop uncontrolled growth in a wide variety ... Oxford, funded in part by the Biotechnology and Biological Sciences ...
Cached Biology News:Gap-climbing fruit flies reveal components of goal-driven behaviors 2NIH renews network focused on how genes influence drug responses 2NIH renews network focused on how genes influence drug responses 3NIH renews network focused on how genes influence drug responses 4Fruit fly studies open new window on cancer research 2
... Peptide sequences: Two separate vials ... to the same sequence used as ... (Catalog No. 160890) ... Cayman's guanylate cyclase polyclonal antiserum (Catalog ...
... 3B8A10. Immunogen: Recombinant ... C-terminal region of human ... for the human ubiquilin ... (positive control: 293 cells). ...
... PinPoint™ Vector Sequencing Primer is designed for ... Vectors (Cat.# V2031, V2051, V2061). The primer ... at nucleotides 325343, approximately 4050 base pairs ... can be used to determine if an ...
... The versatile Zymo-Spin I-96 Plate can be ... manifolds for the large-scale (i.e., 96-well) purification ... polypropylene construction and unique silica-based matrix make ... g DNA or RNA in = 10 ...
Biology Products: